-
What are the advantages of ABI 8 townhouses and the requirements that need to be met for production?
Time of Update: 2022-09-07
1 ml) design reduces contamination caused by condensation, and is suitable for experiments with overnight insulation, reducing the evaporation of the reaction solution and improving the fluorescence signal transmission intensity in qPCR.
-
Target enrichment technologies for ABI SOLiD
Time of Update: 2020-11-01
while Nimblegen has developed target enrichment chip for the Genome Sequencer 20, nothing similar has been done for the SOLiD system, as far as I know.
-
ABI Solid Sequencing
Time of Update: 2020-10-26
Now that many of these mammalian genomes have been sequenced scientists are attempting to provide an epigenetic map of DNA methylation for each tissue type within the body.
The SOLiD method utilizes random 8-mer probes with the 1st and 2nd position containing dinucleotides which are semi-degeneratively labeled with a fluorescent dye.
-
AAC: Hepatitis B in the study of the new drug ABI-H0731 can inhibit the formation of cccDNA, is expected to completely cure hepatitis B.
Time of Update: 2020-10-10
ABI-H0731 (731) is the first generation of HBV core inhibitors developed by Assembly Biosciences to treat chronic hepatitis B (CHB) and is currently undergoing a joint drug evaluation with NrtI in Phase 2 clinical studies.
-
Factors of worsening conditions in Patients with ABI with GCS score of 13-15
Time of Update: 2020-06-27
Nearly 95 percent of patients with brain injury (TBI) had a GCS rating of 13-15 in the early stages of injury, and the treatment options for patients with mild brain injury who were still well-conscio
-
FDA grants ABI-H0731 fast-track determination for treatment of HBV infection patients
Time of Update: 2020-06-11
recently, the U.S FDA , which has been awarded a drug for the treatment of patients with chronic hepatitis B virus (HBV) infection, announced ABI-H0731, a core protein inhibitor for Assembly B
-
Genesis and Affibody partner on autoimmune innovation drug ABY-035
Time of Update: 2020-05-30
Under the agreement, Affibody will receive a down payment of $10 million, up to $215 million in registration and sales milestone payments, as well as a sales commission in the Genesis commercializatio